Introduction
There are at least two molecular pathways to sporadic colorectal cancer (CRC), the chromosomal instability (CIN) pathway and the CpG island methylator phenotype (CIMP) pathway (Shen et al., 2007b; Grady and Carethers, 2008; Issa, 2008) . The CIN pathway accounts for approximately 80% of CRC, with aneuploidy providing the necessary genetic instability to drive the adenoma-carcinoma sequence (Vogelstein et al., 1988; Fearon and Vogelstein, 1990; Grady and Carethers, 2008) . Cancers that develop from this pathway are frequently distal, microsatellite stable and arise from colorectal adenomas (Vogelstein et al., 1988; Fearon and Vogelstein, 1990) . In contrast, CIMP pathway cancers show less aneuploidy with primarily epigenetic rather than genetic instability (Goel et al., 2007; Grady and Carethers, 2008) . In CIMP cancers, promoter methylation-induced transcriptional silencing of important tumor-suppressor genes has an important role in tumor biology (Jass et al., 2002; Jass, 2007; Grady and Carethers, 2008) . BRAF or occasionally KRAS mutation-induced activation of RAS-RAF-MEK-ERK signaling is another important event in CIMP carcinogenesis (Jass et al., 2002; Kambara et al., 2004; Weisenberger et al., 2006; Shen et al., 2007b) . In contrast to the CIN pathway, CIMP cancers frequently develop within the proximal colon, arise from serrated rather than adenomatous polyps, are more common in elderly females and are associated with distinct survival and treatment outcomes (Samowitz et al., 2005; Spring et al., 2006; Weisenberger et al., 2006; Jass, 2007; Shen et al., 2007a; Ogino et al., 2009) . The molecular signatures of these pathways are already evident within their precursor polyps (Spring et al., 2006) , and thus pathway divergence must occur at the beginning of carcinogenesis or even before.
In CRCs, DNA methylation undergoes two fundamental changes. There is progressive global hypomethylation of the genome, particularly of repetitive DNA sequences such as LINE-1, which may promote aneuploidy Gaudet et al., 2003; Esteller, 2008) . There is also a simultaneous and discrete hypermethylation that targets the promoter region of certain genes (Tycko, 2003; Goel et al., 2007; Widschwendter et al., 2007; Esteller, 2008; Ogino et al., 2008) . The genes methylated in cancer are further characterized as 'type A' (age-related) genes and 'type C' (cancerspecific) genes . Generally, 'type A' genes are methylated in both normal and neoplastic tissue, with the degree of methylation proportional to the age of tissue (Ahuja et al., 1998; Ahuja and Issa, 2000) . The hypermethylation of many 'type A' genes may not be directly implicated in colorectal carcinogenesis (Ahuja et al., 1998) , but may still be relevant as an indicator of tissue 'aging', as well as of the broader epigenetic environment (Issa et al., 1994 (Issa et al., , 2001 Ahuja et al., 1998; Ahuja and Issa, 2000) . The methylation of 'type C' genes, however, is more specific for neoplastic tissues (Ahuja et al., 1998; Ahuja and Issa, 2000; Issa et al., 2001; Shen et al., 2005) . Although methylation of certain 'type C' genes segregates very closely with, and indeed defines, CIMP CRC, there are other 'type C' genes in which methylation occurs less discriminately in both CIMP and CIN cancers. This suggests either some overlap between the CRC pathways or, perhaps, the existence of multiple CIMP pathways (Weisenberger et al., 2006; Shen et al., 2007b) .
In 1994, Issa et al. (1994) developed the concept that CpG island methylation within the background mucosa may predispose to CRC. Their study showed that methylation of ESR1, a quintessential 'type A' gene, increased with age and was higher in the distal colorectum, a finding that has since been replicated in other markers (Horii et al., 2008) . These results and the discovery of genes having high levels of methylation within peritumoural 'normal' mucosa suggested that mucosal DNA methylation could be an important marker of, or even a biological prelude to, colorectal carcinogenesis (Issa et al., 1994; Ahuja et al., 1998; Nakagawa et al., 2001; Suzuki et al., 2004; Giovannucci and Ogino, 2005; Shen et al., 2005; Minoo et al., 2006) . Several studies have now developed this work and contrasted DNA methylation in histologically normal mucosa from patients with and without colorectal neoplasia. The results are mixed. Some have reported no association with pathology, others that patients with polyps have increased methylation within their colorectal field and two recent reports have even suggested an inverse association between the presence of colorectal neoplasia and background mucosal methylation (Ye et al., 2006; Al-Ghnaniem et al., 2007; Belshaw et al., 2008; Horii et al., 2008; Ally et al., 2009; Figueiredo et al., 2009; Menigatti et al., 2009) . Reconciling these discrepant results is limited by nonstandardized mucosal sampling, the important confounders of age and region, the use of variable marker panels and techniques and that adenomas may not be an adequate pathological end point when evaluating methylation markers more closely associated with the CIMP pathway.
To address these issues, we conducted a prospective colonoscopic study designed to characterize DNA methylation along the colorectum, to determine the factors associated with mucosal methylation and to examine whether differences in mucosal methylation could help to predict the presence of adenomas and serrated polyps elsewhere in the colorectum.
Results

Patients
The colonoscopy series included 50 patients with normal colonoscopies, 88 diagnosed with an adenomatous lesion and 32 with proximal serrated polyps (PSPs). Patient details, colonoscopic indications and diagnoses are presented in Table 1 .
DNA methylation throughout the normal colorectum: age, sex and site 'Type A' methylation was detected within the normal mucosa in all patients. 'Type C' markers, in which methylation is relatively specific for neoplastic tissue, DNA methylation of the colorectum DL Worthley et al had much lower levels of methylation within the normal mucosa ( Figure 1 ). There was uniform concordance in methylation between 'type A' genes, which is probably because of the strong and direct correlation between patient age and 'type A' (age-related) methylation (Figure 2 and  Supplementary Table 2 ). HIC1 was the only 'type A' marker that did not show a significant correlation with age (r ¼ 0.13, P ¼ 1.0). There were no significant correlations between age and quantitative levels of methylation for any of the other 'type C' markers, the mean CIMP Z-score or for LINE-1 (Supplementary Table 2 ). Although quantitative 'type C' methylation was not associated with patient's age, there were still some interesting associations when methylation was categorized as detectable or undetectable. As stated in the introduction, elderly women are predisposed to CIMP CRC, and MLH1 methylation is important in CIMP tumorigenesis. Interestingly, a greater proportion of women older than 50 years of age, compared with younger women, had detectable colorectal methylation of MLH1 (that is, MLH1 percent of methylated reference (PMR)>0), 36% vs 11%, P ¼ 0.020 (Fisher's exact).
In contrast to 'type A' methylation, there was considerable heterogeneity in methylation among 'type C' markers (Supplementary Table 2 ). There was, however, a small group of 'type C' markers, MINT31, IGF2 and NEUROG1, which were closely correlated both within this subgroup and also with the 'type A' markers GATA5, HPP1 and SFRP1 (Supplementary Table 2 ). MINT2 also showed some significant correlations with 'type A' genes ESR1, HPP1 and SFRP1 (Supplementary Table 2 ). It is possible that these markers exhibit some overlapping 'type A' and 'type C' traits or, perhaps, represent a specific and unique subset altogether.
There were only relatively modest differences in DNA methylation between the sexes. Both pancolorectal MINT2 and LINE-1 showed slightly higher levels of methylation in males, median values 1.4 vs 1.8 (PMR) P ¼ 0.008 and 72% vs 73% P ¼ 0.027, respectively.
There was also a borderline association between higher pancolorectal ESR1 methylation in females, median PMR 2.9 vs 2.7, P ¼ 0.0499. No other markers showed sex-specific differences in methylation.
Consistent with earlier studies, we found that the majority of 'type A' markers had significantly greater methylation in the distal compared with the proximal colorectum (Table 2) . Furthermore, ESR1, HIC1, HPP1, SFRP1 and MINT2 showed a clear methylation gradient along the colorectum (Figure 3 ). MINT31, SOCS1 and CACNA1G also showed significantly higher methylation distally, but did not show the same colorectal gradient and their absolute differences were relatively modest (Table 2 ). In contrast, GATA5 and IGF2 had higher proximal methylation. There were no regional differences in any of the other markers (Table 2) .
DNA methylation and smoking
Smokers, particularly current smokers, had significantly lower levels of DNA methylation for 'type A' and CIMP panels, as well as for MINT31 (P ¼ 0.0014, P ¼ 0.025 and P ¼ 0.018, Supplementary Figure 1 ). There was not, however, any significant association between smoking and LINE-1 methylation (P ¼ 0.46) or for any of the other 'type C' markers.
DNA methylation and its associations with colorectal pathology As outlined above, 'type A' marker methylation within the normal colorectal mucosa increases distally and with increasing patient's age, suggesting 'type A' methylation as a potential contributor to early colorectal carcinogenesis (Issa et al., 1994) . The results of our study, however, clearly show that 'type A' marker methylation is lower in the background mucosa of patients with colorectal adenomas compared with those with normal colonoscopies (Figure 4a ). Subsequent stratification by age, to account for the association between age and pathology, reveals a consistent and inverse association between adenomatous pathology and 'type A' methylation (Figures 4b). Importantly, 'type A' methylation within the colorectal field shows an impressive and inverse biological gradient, with the most advanced adenomatous pathology associated with the lowest levels of 'type A' methylation within the mucosal field (Figures 4c and d) . Consistent with these results, pancolorectal MINT31 methylation and the mean CIMP Z-score results are also significantly lower in the background mucosa of patients with adenomas compared with those with normal colonoscopies, median MINT31 PMR 0.24 vs 0.40, P ¼ 0.0004 and mean CIMP Z-scores of À0.10 vs 0.050, P ¼ 0.040. However, there were no significant associations between methylation of the remaining markers (MINT2, MLH1, MGMT, CDKN2A or LINE-1) and colorectal adenomas.
The CIMP pathway to carcinogenesis is characterized by increased CIMP-panel methylation (Weisenberger et al., 2006; Grady and Carethers, 2008) . This molecular DNA methylation of the colorectum DL Worthley et al signature was reflected in the background mucosa of patients with PSPs, the precursor to the CIMP pathway ( Figure 5) . Specifically, the CIMP methylation Z-score revealed a clear biological gradient, with the most advanced serrated neoplasia associated with the greatest background mucosal methylation ( Figure 5 ; P ¼ 0.030 with a significant trend across the groups, P ¼ 0.033). There were no other significant pathological trends in quantitative methylation for 'type A' markers, LINE-1 or any of the other individual 'type C' markers and serrated neoplasia.
Given the importance of MLH1 methylation in CIMP carcinogenesis and its increased detection in the background mucosa of older women, we analyzed whether detectable methylation of MLH1 was associated with PSPs. Of those patients with detectable proximal MLH1 methylation, 37% had PSPs compared with only 16% of those without (P ¼ 0.011).
Clinical and demographic variables and colorectal pathology
In addition to the univariate associations between DNA methylation and pathology, there were also a number of important patient characteristics associated with colorectal adenomas. Patients with colorectal adenomas were significantly older (65 vs 55 years, P ¼ 0.0013), more frequently male (57 vs 36%, P ¼ 0.019) and more likely to have had a personal history of colorectal neoplasia (74 vs 16%, P ¼ 0.002) than were patients with normal colonoscopies. This is consistent with the established risk factors for CRC (AustralianCancerNetwork, 2005) . In our study population, significant family history of colorectal neoplasia was not associated with the diagnosis of adenomas (P ¼ 0.90). There were no significant univariate associations between clinical and demographic variables and the presence of PSPs. Multivariate analysis of DNA methylation and colorectal pathology To determine the clinical and methylation variables that were independently associated with pathology, we performed multivariate logistic regression as described in the methods section. The mean 'type A' methylation Zscore had a strong, inverse association with the diagnosis of any adenomatous lesion, advanced neoplasia and even CRC (Table 3) . Age and previous colorectal neoplasia were independently associated with the occurrence of adenomas. The mean CIMP methylation Z-score was significantly associated with advanced PSPs (Table 3) . Thus, the univariate associations between methylation and pathology were confirmed by the multivariate results.
Discussion
This study investigated how mucosal DNA methylation varied with age, colorectal region and the presence of pathway-specific pathology. The background levels of 'type A' and CIMP methylation were independently associated with the development of CIN and CIMP pathway precursors, respectively. This is the first colonoscopic study to show that DNA methylation within the colorectal mucosa can independently predict pathway-specific predisposition to CRC. Furthermore, DNA methylation within the 'type A' and CIMP panels was related to the pathological stage within each pathway (Figures 4 and 5) . Although only four patients had CRC, because of our prospective study design, the CIN pathway field events described were still pertinent to cancer and to adenomas. Despite the low numbers, there was still an independent, significant and inverse association between 'type A' methylation and cancer on multivariate analysis (Table 3) . Furthermore, patients with cancers had, for a given age, the very lowest levels of background 'type A' methylation ( Figure 4b ). This placed the adenocarcinoma field at one extreme of a progressive, epigenetic field gradient, apparently accompanying the adenoma-carcinoma sequence. This raises the exciting possibility that CRC biology is predestined by very early molecular events reflected by DNA methylation within the colorectal field. The majority of 'type A' markers showed increasing methylation with age, as well as increasing methylation along the colorectum. Thus, 'type A' methylation has been suggested to contribute to distal CRC in elderly patients (Issa et al., 1994) . Our study, however, suggested the opposite. 'Type A' methylation was actually highest in elderly normal patients, whereas those with colorectal adenomatous lesions had significantly lower levels of 'type A' methylation. The positive correlation between 'type A' methylation and age supports the concept that 'type A' methylation reflects the mitotic 'age' of a tissue, an epigenetic record of cell turnover (Ahuja et al., 1998; Ahuja and Issa, 2000; Issa et al., 2001; Kim et al., 2005) . Thus, 'type A' methylation, rather than being a prelude to cancer (Issa et al., 1994; Ahuja et al., 1998; Ahuja and Issa, 2000) , might represent a component of 'normal' aging. Cellular senescence protects against cancer (Smith and Pereira-Smith, 1996; Ishikawa, 2003; Hornsby, 2007) . Thus, it is conceivable that impaired senescence of the colorectal mucosa, as recorded by attenuated age-specific 'type A' methylation, could reflect a biological imbalance between DNA repair, regeneration and aging, and a predisposition to adenomas (Smith and Pereira-Smith, 1996; Ishikawa, 2003; Hornsby, 2007; Hoeijmakers, 2009) . Our findings agree with two recently published studies, each reporting lower ESR1 methylation in the background mucosa of patients with advanced adenomas and CRC (Belshaw et al., 2008; Horii et al., 2008) .
Although 'type A' methylation within the colorectal field was inversely associated with the diagnosis of colorectal adenomas, within the neoplastic lesion itself, 'type A' methylation is greatly increased (Supplementary Figure 2 ) (Belshaw et al., 2008) . One expects a cancer field to reflect, often in an attenuated form, some of the preliminary genetic or epigenetic aberrations characteristic of cancers from that field (Giovannucci and Ogino, 2005; Shen et al., 2005) . In our study, however, the reverse was true. We hypothesize that it is neoplasia-associated events, potentially including increased proliferation and oxidative damage, which promote de novo 'type A' CpG island methylation (Issa et al., 2001) . It is quite possible that epigenetic silencing of 'type A' genes ultimately promotes neoplasia (Issa et al., 1994; Ahuja et al., 1998; Chen et al., 2004; Suzuki et al., 2004 ), but we propose that 'type A' methylation is originally the consequence rather than the cause of carcinogenesis. Alternatively, 'type A' methylation could still be an initial but non-rate-limiting event in the CIN pathway. Perhaps cells with 'type A' methylation are well disposed to develop into adenomas once a rate-limiting event such as APC mutation has occurred. Thus, adenomas and cancers that emerge from these cells exhibit high levels of 'type A' methylation. This hypothesis, however, does not explain why 'type A' methylation in the field is inversely associated with adenomas.
This study found an inverse association between background 'type A' methylation and colorectal adenomas, the pathological precursors to the CIN pathway. There is already an established relationship between global DNA hypomethylation and CIN in cancer Gaudet et al., 2003; Chen et al., 2007; Esteller, 2008; Ogino et al., 2008) . Thus, one unifying hypothesis could be that relative 'type A' hypomethylation simply reflects global genomic hypomethylation, as is measured by LINE-1, which in turn predisposes the mucosal field to CIN. In our study, however, there was no association between LINE-1 methylation and concomitant pathology. This is consistent with the report by Figueiredo et al. (2009) .
A more biologically intuitive relationship was evident between 'type C' methylation and serrated polyps, the precursors to the CIMP pathway. CpG island methylation is likely to develop through the clonal expansion of stem cells from a single crypt to ultimately produce a small patch of clonal, epigenetically disturbed epithelium (Preston et al., 2003) . When sampling normal mucosa by random biopsy, aberrantly methylated DNA is likely to contribute very little to the total mucosal DNA. Thus, even low levels of methylation of important 'type C' genes could reflect the presence of small patches of methylated epithelium primed to develop into future serrated polyps (Nuovo et al., 2006) . The greater prevalence of MLH1 methylation in older women and the association that we found between MLH1 methylation and PSPs suggest that field-related increases in MLH1 methylation might contribute to the development of CIMP CRC in older women. Other groups have also observed increased MLH1 methylation within the background mucosa of older women (Menigatti et al., 2009 ) and in patients with sporadic microsatellite instability high cancers (Nakagawa et al., 2001) .
Our study did not directly test for epigenetic mucosal gradients surrounding pathology. Such a phenomenon was well demonstrated by mucosal mapping in MGMTmethylated CRCs (Shen et al., 2005) . We did find, however, that proximal MLH1 methylation, rather than pancolorectal or distal MLH1 methylation, was most closely associated with PSPs. For the other outcomes, however, we could not show regionally specific disease associations. Although there is mounting evidence suggesting the importance of 'type C' marker methylation in localized, epigenetic pathological fields (Nakagawa et al., 2001; Shen et al., 2005) , we suspect that attenuated 'type A' methylation is more likely to represent a global colorectal event.
Many 'type A' markers, including ESR1, HIC1, SFRP1 and HPP1, showed a clear regional methylation gradient that increased from the proximal to the distal colorectum. It is possible that luminal short-chain fatty (van Munster et al., 1994) . Future studies should investigate whether there are important luminal or epithelial influences on mucosal epigenetics. In our study, smoking was inversely associated with DNA methylation. Theoretically, smoking-related attenuation of colorectal methylation could reflect the anti-inflammatory effects of nicotine in the colon or is perhaps explained by some confounding nutritional disturbance that is more common in smokers (Sandborn et al., 1997) . It would be interesting to explore this area, particularly given the fact that both smoking and lower levels of 'type A' methylation seem to be associated with colorectal adenomas (Botteri et al., 2008) . Our study suggested that CRC pathway divergence precedes carcinogenesis, with background mucosal methylation defining both the at-risk patients as well as the at-risk pathways. A critical issue is whether incident pathology is similarly associated with the colorectal field and thus if DNA methylation could be used as a mucosal biomarker in future trials or even help to refine existing colonoscopic surveillance strategies.
Materials and methods
Patients, clinicopathological details and sampling DNA methylation was investigated in normal-appearing colorectal mucosal biopsy specimens taken during colonoscopy. A total of 166 patients scheduled for outpatient colonoscopy were prospectively recruited from the Royal Brisbane and Women's Hospital in Brisbane and the Flinders Medical Centre in Adelaide, Australia. Patients were excluded if they were anticoagulated or had a history of inflammatory bowel disease, familial adenomatous polyposis or hyperplastic polyposis. All subjects gave written, informed consent and the study was approved by the local institutional review boards.
Patients were asked about their smoking and personal and family history of colorectal neoplasia. A significant family history was defined as at least one first-degree relative diagnosed with CRC less than 55 years, or two first-or second-degree relatives (on the same side of the family) diagnosed with CRC at any age (AustralianCancerNetwork, 2005) . At colonoscopy, all identified polyps were removed and the vast majority were retrieved for histology. The study defined advanced adenomas as either >1 cm in diameter or showing high-grade dysplasia or villous pathology (AustralianCancerNetwork, 2005) .
The pathological precursor to the CIMP pathway was defined as the PSP, which included any serrated polyp (hyperplastic polyp, sessile serrated adenoma, traditional serrated adenoma or mixed polyp) diagnosed proximal to the splenic flexure (Jass et al., 2002; East et al., 2008 ). An advanced PSP was defined as a PSP that was large (>1 cm) or that had advanced features (sessile serrated adenomas, traditional serrated adenomas and mixed polyps).
During colonoscopy, all patients had four mucosal biopsy samples taken from the cecum, the transverse colon, the sigmoid colon and the rectum. The mucosal biopsy samples were snap frozen in liquid N 2 and stored at À80 1C until processing.
DNA methylation DNA was extracted from the frozen biopsy samples, purified and bisulfite modified using the AllPrep DNA/RNA Mini and EpiTect Bisulfite Kits (Qiagen Pty Ltd, Hilden, Germany), respectively. DNA methylation was quantified at five 'type A' genes ESR1, GATA5, HIC1, HPP1 and SFRP1 (Issa et al., 1994; Young et al., 2001; Akiyama et al., 2003; Chen et al., 2004; Suzuki et al., 2004) and 10 'type C' markers MLH1, CDKN2A, MGMT, MINT2, MINT31, CACNA1G, IGF2, RUNX3, NEUROG1 and SOCS1 Issa, 2004; Shen et al., 2005 Shen et al., , 2007b Weisenberger et al., 2006) . Specific 'type A' genes were selected for their relevance to colorectal neoplasia and for evidence (unpublished data) that each had relatively high methylation within peritumoral 'normal' mucosa. The first five 'type C' markers were chosen for their importance in the biology and molecular classification of CRC Issa, 2004; Shen et al., 2005 Shen et al., , 2007b . The final five 'type C' markers comprise a current CIMP CRC panel (Weisenberger et al., 2006) . In cancer, methylation of these CIMP markers is strongly associated with CIMP features, including BRAF mutation, proximal location and sporadic microsatellite instability (Weisenberger et al., 2006) .
Methylation was quantified by MethyLight, a methylationspecific, probe-based, RT-PCR technique, adapted from a published method (Supplementary methods and Supplementary Table 1 ) (Weisenberger et al., 2006) . DNA methylation at each promoter region was reported as PMR ¼ 100 Â ((methylated reaction/Alu) sample /(methylated reaction/Alu) M.SssIÀreference ) (Weisenberger et al., 2006) . Methylation was also measured at LINE-1, which has been correlated with global DNA methylation, as well as CIN (Ogino et al., 2008) . LINE-1 methylation was quantified by pyrosequencing using the PyroMark kit (Biotage, Uppsala, Sweden) and the PSQ HS 96 System (Biotage), as previously described (Ogino et al., 2008; Irahara et al., 2009) . LINE-1 methylation was reported as the mean percentage of methylated cytosines (Ogino et al., 2008) .
Statistical analysis
A PMR was calculated for each marker (or % for LINE-1), at each of the four sites, in each patient. In addition, an average proximal (mean of cecum and transverse colon), distal (mean of sigmoid colon and rectum) and pancolorectal (mean of all four sites) results were recorded for each patient. Correlations were analyzed by Spearman's rank (r) coefficient, with Bonferroni's correction for multiple comparisons. Matched analysis of methylation and region used Friedman's test and the Wilcoxon signed-rank test with Bonferroni's correction for post hoc pairwise analysis between regions. Distal and proximal levels of methylation were analyzed by a paired t-test. In patients with and without certain pathologies, methylation was analyzed by ANOVA, Kruskal Wallis, Pearson's w 2 and Fisher's exact test, where appropriate, using Stata Statistical Software, version 10 (StataCorp, College Station, TX, USA).
In addition to single marker analyses, an average Z-score was also calculated for five 'type A' genes (ESR1, GATA5, HIC1, HPP1 and SFRP1) and 5 'type C' genes constituting the CIMP panel (IGF2, NEUROG1, CACNA1G, RUNX3 and SOCS1) (Weisenberger et al., 2006) , as previously described (Konishi et al., 2007; Shen et al., 2007b) . To calculate the mean Z-score, the pancolorectal PMR for each marker was log transformed, the transformed results were standardized according to their distribution and then a mean Z-score was calculated across five markers in each panel.
Multivariate logistic regression was used to determine the variables that were independently associated with pathology. The initial model included all clinically relevant risk factors for colorectal neoplasia (age, sex, significant family history and a personal history of colorectal neoplasia), as well as the mean 'type A' and CIMP methylation Z-scores. Variables with a P value 40.05 were removed in a backward stepwise manner.
Abbreviations CIMP, CpG island methylator phenotype; CIN, chromosomal instability; CRC, colorectal cancer; PMR, percent of methylated reference; PSP, proximal serrated polyp.
